NxStage Medical Inc. | Mutual Funds
Mutual Funds that own NxStage Medical Inc.
Vanguard Small Cap Index Fund
1,672,219
2.54%
22,593
0.05%
07/31/2018
Vanguard Total Stock Market Index Fund
1,648,679
2.5%
2,024
0.01%
07/31/2018
iShares Russell 2000 ETF
1,390,607
2.12%
-744
0.08%
09/06/2018
Vanguard Small Cap Growth Index Fund
954,047
1.46%
13,152
0.11%
07/31/2018
Vanguard Extended Market Index Fund
885,966
1.35%
0
0.04%
07/31/2018
Government Pension Fund - Global (The)
845,072
1.29%
393,314
0%
12/31/2017
Flossbach von Storch - Multiple Opportunities II
810,799
1.24%
810,799
0.36%
03/31/2018
Arbitrage Fund (The)
779,910
1.19%
-49,416
2.15%
02/28/2018
GMO Implementation Fund
681,128
1.04%
427,310
0.17%
02/28/2018
iShares Russell 2000 Growth ETF
638,887
0.97%
0
0.16%
09/06/2018
| Address |
350 Merrimack Street
Lawrence Massachusetts 01843
United States
|
|
Employees
|
- |
| Website |
http://www.nxstage.com |
| Updated |
09/14/2018 |
| NxStage Medical, Inc. is a medical technology company, which develops, manufactures, and markets products for the treatment of ESRD and acute kidney failure. It operates through the following business segments: System One, In-Center, and Services. The System One segment engages in the sale and rental of the System One and PureFlow SL equipment and the sale of disposable products in the home and critical care markets. |
